RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Mereo Biopharma Group - Stock

Mereo Biopharma Group P/S 2024

Mereo Biopharma Group P/S

1.01

Ticker

MREO

ISIN

US5894921072

WKN

A2PEYJ

As of Jun 21, 2024, Mereo Biopharma Group's P/S ratio stood at 1.01, a 68.33% change from the 0.6 P/S ratio recorded in the previous year.

The Mereo Biopharma Group P/S history

Mereo Biopharma Group Aktienanalyse

What does Mereo Biopharma Group do?

Mereo BioPharma Group plc was founded in 2015 and is based in Reading, UK. The company is a pharmaceutical industry company that focuses on the development of treatments for rare and unmet medical needs. Mereo BioPharma is an emerging biotechnology company that discovers, develops, and markets innovative drugs. The company employs an experienced team of scientists and researchers dedicated to developing therapies that address unmet medical needs. Mereo BioPharma specializes in four areas of interest in which it is actively working on new developments: oncology, rare diseases, gynecological and endocrine disorders, and respiratory diseases. The company aims to advance innovative drug developments that focus on rare and unmet medical needs. These typically have received little attention from larger, established pharmaceutical companies. However, they represent a tremendous opportunity to identify and successfully bring to market high-quality and effective drugs. Mereo BioPharma is listed on the London Stock Exchange (AIM) and has a strong financial foundation. Mereo is preparing to launch two new products - Alvelestat and Setrusumab - for the treatment of respiratory diseases and osteogenesis imperfecta. Mereo's business model is based on a multi-stage development pipeline: from the discovery of potential drug candidates to clinical trials and marketing. The company works closely with established partners to pool the necessary resources and expertise required for the development and successful commercialization of an outstanding product. Alvelestat is a unique therapy specifically developed for patients with alpha-1 antitrypsin deficiency. The drug is used to treat lung and liver diseases often associated with this condition. It is currently in Phase II of clinical development. Setrusumab is an innovative product for the treatment of osteogenesis imperfecta, a rare bone disorder often diagnosed in early childhood. The drug is currently in Phase III of the approval process. The company's future plans include expanding its pipeline to create treatment options for patients worldwide. Mereo utilizes advanced technologies and modern methods to foster research, development, and clinical studies and ensure the success of its products in the market. Mereo BioPharma Group plc is a young, exciting company specializing in the development of drugs for the treatment of rare and unmet medical needs. The company focuses on three strategic priorities: research and development of innovative drugs, collaboration with strong partners, and marketing and distribution of its products. Mereo has a strong financial foundation and is committed to expanding its pipeline to meet new patient needs. Mereo Biopharma Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Mereo Biopharma Group's P/S Ratio

Mereo Biopharma Group's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Mereo Biopharma Group's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Mereo Biopharma Group's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Mereo Biopharma Group’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Mereo Biopharma Group Stock

What is the price-to-earnings ratio of Mereo Biopharma Group?

The price-earnings ratio of Mereo Biopharma Group is currently 1.01.

How has the price-earnings ratio of Mereo Biopharma Group changed compared to last year?

The price-to-earnings ratio of Mereo Biopharma Group has increased by 68.33% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Mereo Biopharma Group high compared to other companies?

Yes, the price-to-earnings ratio of Mereo Biopharma Group is high compared to other companies.

How does an increase in the price-earnings ratio of Mereo Biopharma Group affect the company?

An increase in the price-earnings ratio of Mereo Biopharma Group would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Mereo Biopharma Group affect the company?

A decrease in the price-earnings ratio of Mereo Biopharma Group would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Mereo Biopharma Group?

Some factors that influence the price-earnings ratio of Mereo Biopharma Group are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Mereo Biopharma Group pay?

Over the past 12 months, Mereo Biopharma Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mereo Biopharma Group is expected to pay a dividend of 0 GBP.

What is the dividend yield of Mereo Biopharma Group?

The current dividend yield of Mereo Biopharma Group is .

When does Mereo Biopharma Group pay dividends?

Mereo Biopharma Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mereo Biopharma Group?

Mereo Biopharma Group paid dividends every year for the past 0 years.

What is the dividend of Mereo Biopharma Group?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mereo Biopharma Group located?

Mereo Biopharma Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mereo Biopharma Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mereo Biopharma Group from 6/21/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 6/21/2024.

When did Mereo Biopharma Group pay the last dividend?

The last dividend was paid out on 6/21/2024.

What was the dividend of Mereo Biopharma Group in the year 2023?

In the year 2023, Mereo Biopharma Group distributed 0 GBP as dividends.

In which currency does Mereo Biopharma Group pay out the dividend?

The dividends of Mereo Biopharma Group are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Mereo Biopharma Group

Our stock analysis for Mereo Biopharma Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mereo Biopharma Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.